This consensus statement was initiated based on the understanding that patients with advanced lung or heart disease are not currently being treated consistently and effectively for relief of dyspnea. The purpose is to summarize available evidence in order to improve the care and treatment of dyspnea in this population. An expert panel of specialists in pulmonary medicine, cardiology, nursing, and palliative care developed our fi ndings. Selection of the expert Donald A. Mahler , MD, FCCP ; Paul A. Selecky , MD, FCCP ; Christopher G. Harrod , MS ; Joshua O. Benditt , MD, FCCP ; Virginia Carrieri-Kohlman , DNSc ; J. Randall Curtis , MD, FCCP ; Harold L. Manning , MD, FCCP ; Richard A. Mularski , MD, MSHS, MCR, FCCP ; Basil Varkey , MD, FCCP ; Margaret Campbell , RN, PhD ; Edward R. Carter , MD, FCCP ; Jun Ratunil Chiong , MD, FCCP ; E. Wesley Ely , MD, MPH, FCCP ; John Hansen-Flaschen , MD, FCCP ; Denis E. O'Donnell , MD ; and Alexander Waller , MD Background: This consensus statement was developed based on the understanding that patients with advanced lung or heart disease are not being treated consistently and effectively for relief of dyspnea. Methods: A panel of experts was convened. After a literature review, the panel developed 23 statements covering five domains that were considered relevant to the topic condition. Endorsement of these statements was assessed by levels of agreement or disagreement on a five-point Likert scale using two rounds of the Delphi method. Results: The panel defi ned the topic condition as "dyspnea that persists at rest or with minimal activity and is distressful despite optimal therapy of advanced lung or heart disease." The fi ve domains were: measurement of patient-reported dyspnea, oxygen therapy, other therapies, opioid medications, and ethical issues. In the second round of the Delphi method, 34 of 56 individuals (61%) responded, and agreement of at least 70% was achieved for 20 of the 23 statements. Conclusions: For patients with advanced lung or heart disease, we suggest that: health-care professionals are ethically obligated to treat dyspnea, patients should be asked to rate the intensity of their breathlessness as part of a comprehensive care plan, opioids should be dosed and titrated for relief of dyspnea in the individual patient, both the patient and clinician should reassess whether specifi c treatments are serving the goal of palliating dyspnea without causing adverse effects, and it is important for clinicians to communicate about palliative and end-of-life care with their patients.
breathlessness as part of a comprehensive care plan. 2. The patient-reported rating of breathlessness should be routinely documented in the medical record to guide management and interdisciplinary care. 3. The assessment of dyspnea should include inquiry into the distress, meaning, and unmet needs that accompany breathlessness. 4 . The use of any particular instrument over another for the measurement of dyspnea is not suggested at the present time. 5. Health-care professionals are ethically obligated to treat dyspnea, and patients and their families should be reassured that they will be provided the means to effectively treat this symptom. 6. Therapies should generally be started with the understanding that the patient and clinician will reassess whether specifi c treatments are serving the goal of palliating dyspnea without causing adverse effects.
Oxygen Therapy for Relief of Dyspnea

7.
Supplemental oxygen can provide relief of dyspnea for patients who are hypoxemic at rest. 8. Supplemental oxygen can provide relief of dyspnea for patients who are hypoxemic during minimal activity.
Other Nonpharmacologic Therapies for Relief of Dyspnea
9. Pursed-lip breathing can be an effective strategy for relief of dyspnea. 10. Relaxation can be an effective strategy for relief of dyspnea. 11. Noninvasive positive pressure ventilation can provide relief of dyspnea.
Opioid Medications for Relief of Dyspnea
12.
Oral and/or parenteral opioids can provide relief of dyspnea. 13. Opioids should be dosed and titrated for the individual patient with consideration of multiple factors (eg, renal, hepatic, pul monary function, and current and past opioid use) for relief of dyspnea. 14. Respiratory depression is a widely held concern with the use of opioids for the relief of dyspnea.
Ethical Issues for Relief of Dyspnea at End of Life
15.
Concerns about contributing to addiction and/or physical dependence should never limit effective treatment or palliation of dyspnea. 16 . The "principle of double effect" provides a rationale for using opioids or sedatives that might hasten death, provided that the purpose of increasing doses is to relieve dyspnea. 17 
D
yspnea is a prominent symptom among patients with advanced lung or heart disease. 1 In a systematic review, the reported prevalence of breathlessness was . 90% in patients with advanced COPD and . 60% in those with advanced heart disease. 2 About 94% of patients with chronic lung disease experience dyspnea in the last year of life. 3 A retrospective analysis of a prospective cohort from the Study to Understand Patient Preferences and Outcomes of Treatment found that dyspnea was the overriding complaint of patients who died of COPD and that "serious dyspnea" was far more common (66%) than "serious pain" (25%). 4 The investigators reported that patients with COPD were more likely to die with poor control of dyspnea than patients who had lung cancer. 5 The perception of dyspnea is considered analogous to the perception of pain and consists of sensory (intensity) and affective (unpleasantness) dimensions. 6 Similar cortical processes appear to underlie the experience of dyspnea and pain. Clearly, both symptoms can result in human suffering. Anxiety, depression, and other psychologic factors occur frequently in patients with advanced disease and infl uence breathlessness. 7 Although uncertainties and questions remain about the exact mechanisms that cause dyspnea, it is a distressing symptom that requires attention, consideration, and treatment by healthcare providers. The purpose of this consensus statement is to infl uence clinical practice and to provide suggestions for the management of dyspnea in patients with advanced lung or heart disease. This topic was proposed based on the understanding that patients are not being treated consistently and effectively for the relief of dyspnea under these conditions. 8 -11 The panel agreed that this consensus statement was intended for care of the patient in whom medical therapy has been optimized, and the focus of treatment is on symptom management, relief of suffering, and maintenance of quality of life. After extensive discussion and consideration, the panel defi ned the target patient population as those with "dyspnea that persists at rest or with minimal activity and is distressful despite optimal therapy of advanced lung or heart disease." "Advanced" stage refers to progressive disease with a limited prognosis.
Methods
Literature Search
The ACCP research methodologist performed a MEDLINE literature search of English language articles on human subjects for the period of 1966 to 2008. The purpose of the literature search was to evaluate published studies on this topic condition and to identify topic domains that would form the basis of the consensus survey. The following search strategy and key terms were used to capture studies relevant to the topic: Patients with cancer were not included in this review because high-quality evidence is available on end-of-life care in this population. However, there are gaps in our knowledge about the management/palliation of breathlessness as experienced daily by pati ents with advanced lung or heart disease.
The literature search was initially limited to randomized controlled trials (RCTs). However, because of the paucity of data, the literature search was expanded to include prospective studies, case series, and systematic reviews. After the initial literature review was completed, each primary author of the different domains reviewed the articles and critically added or removed references or review articles that he/she considered relevant. These additional materials were then reviewed for inclusion/exclusion by the secondary author of the domain and the fi rst three authors of the consensus statement. The materials were then provided to the expert panel for consideration.
Five domains were derived from the results of the literature search and included: measurement of patient-reported dys pnea, oxygen therapy, other nonpharmacologic treatment, opioid medications, and ethical issues. A primary and a secondary author www.chestpubs.org were identifi ed among members of the expert panel to review the results of the literature search and to generate statements for consideration for each of the fi ve domains. Each statement was then reviewed and, if deemed appropriate, revised by the panel members.
Expert Panel Members
The consensus development process was organized following ACCP policy. Participation was obtained by open nomination from the ACCP membership through the ACCP NetWork system. NetWork committees consist of members of the ACCP who are physicians, nurses, or other health-care professionals with a specifi c interest in a particular topic. The expert panel members consisted of cardiopulmonary physicians and nurses who were selected based on their clinical and/or research expertise in evaluating and/or providing care to the patient population. Panel members served as content experts on specifi c domains (key topics) addressed in the consensus statement. Panel members also participated in the devel op ment and initial round of the Delphi survey.
Delphi Method
Endorsement of consensus statements on the management of dyspnea in patients with advanced lung or heart disease was accomplished using a modifi ed Delphi method. 12 The Delphi approach was chosen because it represents an established method of obtaining expert opinion, determining levels of agreement, and evaluating the degree of consensus on a given topic. It has been used widely in various areas of health-care research, including the development of guidelines for best practice, content of curricula, and the defi nition of professional roles and clinical protocols. 13 , 14 Anonymity was derived from the absence of face-to-face interaction. The survey was distributed online, and participants responded independently to the questionnaire. Levels of agreement or disagreement were assessed for each statement on a fi ve-point Likert scale ( Table 1 ) . Responses were accessed by the ACCP research methodologist for statistical analysis and determination of the level of expert consensus and appropriateness of management suggestions.
For the fi rst round, the survey was sent to the 15 expert panel members, who independently rated agreement or disagreement for each of the 23 statements. Based on these responses, each statement was reviewed and modifi ed, if deemed appropriate, to enhance clarity. For the second round, the 23 statements were sent to 56 clinicians from fi ve relevant ACCP specialty NetWork steering committees: Clinical Pulmonary Medicine, Respiratory Care, Airways, Palliative and End-of-Life Care, and Cardiovascular Medicine and Surgery.
Statistical Analysis
Levels of agreement for the Delphi method are presented as percent agreement (rated as 4 or 5 on the Likert scale) as well as the range, mean, and median values. 15 -20 Consensus on a topic can 21 The results of the data analysis derived from the survey are expressed as the percentage of respondents scoring an item either 4 ("somewhat agree") or 5 ("agree"). For the purposes of the consensus statement, agreement among the respondents of Ն 70% for each statement was considered a priori to represent consensus.
, 22
Results
The results of the literature review are presented in tables located in the Appendices. The results of the Delphi survey are presented in Tables 2 to 7 .
Literature Search
The literature search retrieved a total of 13 RCTs, 10 systematic reviews, 10 prospective studies, seven retrospective studies, seven case studies, and two topic reviews that were relevant to the management of dyspnea in patients with advanced lung or heart disease. A summary of these reports is presented in Appendices 1 to 5 . Studies that measured the effectiveness of an intervention for the relief of dyspnea during exercise were excluded from review because the expert panel believed the target patient population would have diffi culty performing exercise testing because of dyspnea at rest or during minimum activity.
Measurement of Patient-Reported Dyspnea
Asking patients to report the severity and/or distress of their breathlessness has been suggested in order to assess its impact on an individual's overall health status and to provide a baseline value to evaluate the response to specifi c therapies. 23 -30 This approach is analogous to the assessment of pain that is mandated in health-care encounters to guide pain awareness and management.
Although dyspnea is multidimensional and includes an affective component, an initial strategy is to ask the patient to report the intensity or severity of breathlessness. 23 -31 Three instruments-the 0 to 10 scale developed by Borg, 32 the visual analog scale, 33 , 34 and the numerical rating scale 35 , 36 -have demonstrated usefulness in assessing breathlessness in patients with advanced disease. In comparative trials, superior performance has not been demonstrated with any of these instruments in patients with advanced lung or heart disease ( Appendix 1 ). 2 , 35 , 37 , 38 Interventions might decrease the unpleasantness or distress associated with dyspnea without decreasing its intensity (as similar to pain).
Oxygen Therapy
Patients With Hypoxemia: Oxygen therapy is the standard of care for the treatment of patients with For patients with advanced lung or heart disease, the use of any particular instrument over another for the measurement of dyspnea is not suggested at the present time. For patients with advanced lung or heart disease, health-care professionals are ethically obligated to treat dyspnea and to reassure patients and their families that they will provide the means to effectively treat this symptom.
For patients with advanced lung or heart disease, therapies should generally be started with the understanding that the patient and clinician will reassess whether specifi c treatments are serving the goal of palliating dyspnea without causing adverse effects. hypoxemia. 39 , 40 However, only a limited number of studies have evaluated the short-term effects of supplemental oxygen therapy on breathlessness at rest in patients with advanced lung disease ( Appendix 2 ). 41 -45 Two studies reported signifi cant improvement in dyspnea with oxygen therapy, 42 , 45 whereas the other two studies found no benefit. 41 , 43 There are no RCTs evaluating the effects of oxygen in reducing breathlessness in patients with advanced heart disease.
Patients Without Hypoxemia:
The literature search strategy used for this consensus statement did not identify any studies evaluating the effects of supplemental oxygen for the relief of dyspnea in patients with advanced lung or heart disease who were not hypoxemic at rest .
Other Nonpharmacologic Approaches
The expert panel chose to focus on several nonpharmacologic approaches that are more commonly used in clinical practice to relieve dyspnea. These include pursed-lip breathing (PLB), cool air movement on the face with a fan, relaxation therapy, and noninvasive positive pressure ventilation (NPPV). A summary of studies on the effectiveness of these treatments in patients with advanced lung or heart disease is presented in Appendix 3 .
46 -57 A Cochrane review has summarized the nonpharmacologic interventions for treatment of breathlessness in advanced stages of malignant and nonmalignant diseases. 57 The literature review also considered studies of anxiolytic medications, antidepressants, phenothiazines, inhaled furosemide, inhaled lidocaine, music therapy, and acupuncture for relief of dyspnea. As there are only a few reports on these interventions in the target patient population, the information was considered insuffi cient to be included in this consensus statement.
PLB: PLB is a breathing strategy often used spontaneously by patients with airway obstruction, particularly those with COPD, to relieve breathlessness. PLB performed during rest improves oxygen saturation and reduces carbon dioxide levels by promoting a slower and deeper breathing pattern. 58 
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For patients with advanced lung or heart disease, opioids should be dosed and titrated for the individual patient with consideration of multiple factors (eg, renal, hepatic, and pulmonary function, and current and past opioid use) for relief of dyspnea.
For patients with advanced lung or heart disease, respiratory depression is a widely held concern with the use of opioids for the relief of dyspnea. 100 4-5 4.7 (5) et al 46 found that 22 patients with COPD reported a modest but signifi cant decrease in breathlessness ( D 0.3 units on the Borg scale; P , .04) and a corresponding reduction in end-expiratory volume with PLB compared with spontaneous breathing.
Fan: Patients with respiratory disease often describe that movement of cool air with a fan or fresh air reduces breathlessness. 61 Laboratory studies have shown that cold air directed on the cheek decreases dyspnea induced in healthy individuals. 62 However, to our knowledge, there are no studies published in peer-review journals that have examined the use of a fan and/or cool air for the relief of dyspnea in patients with advanced lung or heart disease.
Relaxation Therapy: Two studies measured the e ffects of relaxation on perceived dyspnea in patients with COPD at rest. 47 , 48 Gift et al 47 found that patients reported less dyspnea after listening to a recordedrelaxation message compared with sitting quietly. Renfroe 48 reported that progressive muscle relaxation was effective in reducing dyspnea in 20 patients with COPD after each of four weekly sessions ( P 5 .04) but not at the end of the 4-week period.
NPPV:
The rationale for NPPV is that by unloading the respiratory muscles, the decreased work of breathing might provide relief of dyspnea. In three systematic reviews, authors concluded that use of NPPV improved patients' perception of dyspnea in those with advanced COPD or acute respiratory failure. 53 -55 In four RCTs, there was a modest-to-signifi cant improvement in patient-reported dyspnea with NPPV. 49 -52 As relief of dyspnea with NPPV may not relate to changes in arterial blood gases, it is appropriate to reassess the breathlessness experienced by patients receiving such ventilatory support at frequent intervals.
Opioid Medications
Opioids are naturally occurring, semisynthetic, and synthetic drugs that bind to opioid receptors to produce relief of dyspnea. Opioids may have multiple mechanisms of action for symptom relief, including reductions in ventilation, oxygen consumption, sensitivity to hypercapnia, the central perception of dyspnea (similar to the reduction in the central perception of pain), and anxiety associated with dyspnea. 63 Opioids are administered in oral, parenteral, and nebulized forms. Although oral morphine is the most commonly prescribed opioid for the relief of dyspnea, other medications include diamorphine, dihydrocodeine, fentanyl, hydromorphone, and oxycodone. 64 Specifi c concerns about the study designs of various RCTs are that the opioid dose was relatively small, doses were not titrated to achieve a threshold dose for symptom relief, and the dosing intervals may have been too long.
Oral and Parenteral Opioids:
The effects of oral and/or parenteral opioids for relief of dyspnea at rest are variable ( Appendix 4 ). 65 -77 In one review of 13 studies involving patients with a variety of advanced chronic diseases, Jennings and colleagues 63 concluded that morphine was effective in relieving dyspnea (standard mean difference, 2 0.31; CI 2 0.51 to 2 0.31). In two reviews of palliative care, the authors concluded that short-term opioids are effe c t ive in improving dyspnea in patients at the end of life.
, 76
Nebulized Opioids: Opioid receptors are located throughout the respiratory tract. 78 The rationale for the nebulized route of administration is that these medications bind to these opioid receptors and might relieve dyspnea without causing systemic side effects. Although there is anecdotal support for the use of nebulized opioids, data from two RCTs found that nebulized morphine was no better than nebulized saline for relieving dyspnea. 69 , 70 Jennings and collegues 63 concluded that nebulized opioids did not relieve breathlessness.
Adverse Effects With Opioids: Fear of overdosing and the development of respiratory depression are common concerns in caring for patients with advanced lung or heart disease who experience severe dyspnea. Chan et al 79 reported that higher doses of opi oids and benzodiazepines used in the withdrawal of lifesustaining treatment were not associated with a decreased time from withdrawal of life support to death. Other studies found that survival time was unrelated to morphine dosage. 80 -82 Of 11 studies that provided information on arterial blood gases or oxygen saturation, only one study reported any signifi cant changes in oxygenation after opioid administration. 83 Although the arterial carbon dioxide partial pressure increased with opioid use, the value did not exceed 40 mm Hg. 84 Other adverse effects that may occur with opioids include constipation, confusion, drowsiness, hallucinations, nausea/vomiting, and psychosis.
Ethical Issues
The major ethical issues identifi ed in this review include the obligation to treat or palliate dyspnea, appro priate opioid dosing and associated con cerns of www.chestpubs.org addiction, cultural sensitivity, and effective communication ( Appendix 5 ). 85 -92 Many patients with advanced lung or heart disease have a tremendous concern about the experience of dying, and a large component of this anxiety is focused on their breathing diffi culty and "suffocating." 85 , 86 , 93 Recent statements and guidelines emphasize the obligation of physicians and nurses to use available treatments to relieve dyspnea in this patient population. 1 , 30 , 57 The principle of double effect provides a justifi cation for using opioids or sedatives that might hasten death, as long as the purpose of titrating doses is to control or relieve symptoms. 94 Confl ict among clinicians, patients, and family members about treating symptoms may arise when clinicians and family members have different cultural perspectives on end-of-life care. Blackhall et al 87 , 88 posed that clinicians should understand that family members from some cultures may have very different perspectives on the role of the family and who should be involved in decisions about treating symptoms at the end of life. Patients and families may also vary in their perspectives on the value of maintaining consciousness at the end of life and the value of suffering. It is important to anticipate differences in perspectives and be prepared to apply principles of culturally effective end-of-life care to these situations.
There is evidence that patients with advanced lung or heart disease receive poor-quality palliative and end-of-life care compared with patients who have cancer. 5 , 95 -97 One reason these patients may receive poor-quality palliative care is that patient-physician communication about end-of-life care is unlikely to occur. 89 , 90 , 98 Understanding the barriers to this communication may be an important step to improving communication about end-of-life care. 91 Although most patients with advanced disease would like to discuss end-of-life care with their physicians, few physicians discuss such issues with their patients. 89 , 90 , 98 
Delphi Method
For the fi rst round of evaluation for consensus, 12 of the 15 panel members (80%) completed the survey. For the second round of evaluation for consensus, 34 of 56 individuals (61%) completed the survey. Acceptable levels of agreement were obtained for 20 of 23 statements during the second round of the survey ( Tables 2 -6 ). Three statements did not achieve agreement ( Table 7 ) .
Discussion
Despite the high prevalence of dyspnea in patients with advanced lung or heart disease, the current literature review and previous reviews demonstrate the paucity of scientifi c data on the management of this symptom. 1 , 27 , 76 , 99 , 100 The majority of RCTs on this topic have focused on patients with advanced COPD, whereas information addressing dyspnea management in patients with advanced heart disease is quite limited.
With the Delphi method, consensus was achieved on 20 of 23 statements. However, a high level of agree ment among experienced clinicians does not necessarily refl ect clinical practice. With the Delphi method, statements can be revised followed by additional rounds of asking respondents to rate agreement or disagreement. However, panel members believed that this process was unlikely to achieve consensus for three statements ( Table 7 ) . Management suggestions derived from the Delphi method should not be used for performance measurement or for competency purposes, because they are not evidence-based as defi ned by the ACCP Health and Science Policy Committee.
There was consensus that patients with advanced lung or heart disease should be asked to routinely and regularly rate the intensity of breathlessness and that these ratings should be documented in the medical record. Similarly, the American Thoracic Society has stated that symptom management for patients with advanced respiratory disease should rely on a dyspnea scale as reported by the patient to assess its severity and the effects of therapy. 1 Although assessment of a patient's intensity of pain is a requirement, it is not standard practice for health-care providers to ask patients to provide a rating of dyspnea.
There was clear consensus on the use of oxygen to relieve dyspnea in patients with hypoxemia even though the results of four RCTs do not demonstrate a consistent benefi t. The American College of Physicians has recommended that oxygen be used for short-term relief of hypoxemia as part of the management of dyspnea in patients at the end of life. 76 Only 47% of respondents believed that supplemental oxygen would relieve dyspnea that occurs at rest or with minimal activity in patients without hypoxemia. The literature search did not identify any studies that evaluated oxygen therapy in a population of patients without hypoxemia.
Our survey demonstrated consensus for using oral or parenteral opioids to relieve dyspnea, for titrating doses of opioids in individual patients, and for concern about respiratory depression. Previous reviews and statements support these fi ndings. 27 , 43 , 101 -103 However, there was uncertainty among respondents whether nebulized opioids provide equivocal or additional relief of dyspnea compared with systemic delivery. Two systematic reviews concluded that nebulized opioids are no more effective than nebulized placebo for relieving dyspnea. 63 , 76 There was strong consensus relating to various ethical issues for palliating dyspnea, particularly at the end of life. For example, agreement was high that health-care professionals are ethically obligated to treat dyspnea, and that the effectiveness of specifi c treatments and possible side effects should be reassessed by both patients/families and the clinician. Seventy-two percent of respondents agreed with the statement that the principle of double effect provides justifi cation for using opioids or sedatives to relieve dyspnea even though this might hasten death. This principle, along with other ethical issues, emphasizes the importance of communication with the patient and family members and creates an awareness that different perspectives may exist among families and cultures. 
Appendix 1 -Comparison of Instruments to Measure Dyspnea in Advanced Lung or Heart Disease
Summary
This consensus statement was initiated based on the understanding that patients with advanced lung or heart disease are not currently being treated consistently and effectively for relief of dyspnea. The purpose was to provide suggestions to improve the treatment of dyspnea in this patient population. The results of the literature review demonstrated a paucity of scientifi c information on this topic. Using the Delphi method to develop consensus, acceptable agreement was achieved for 20 of 23 statements that covered the domains of measurement of patient-reported dyspnea, oxygen therapy, other nonpharmacologic therapies, opioid medications, and ethical issues. There is a need and opportunity to enhance our knowledge with additional research to improve the management of dyspnea in patients with advanced lung or heart disease.
www.chestpubs.org Bilevel positive airway pressure for pressure preset ventilation or PLV-100 as a home-care volume preset ventilator was used via a nasal or facial mask. The four types (two ventilators and two masks) of NPPV were used for 20 min each, with a randomized sequence.
Appendix 2 -Oxygen Therapy for the Palliation of Dyspnea in Advanced Lung or Heart Disease
Short-term use of bilevel positive airway pressure via either a nasal or facial mask reduces the sense of dyspnea compared with the use of PLV-100, which worsens the sense of dyspnea.
(Continued) 
Miscellaneous nonpharmacologic interventions
Vibration of patient's chest wall, electrical stimulation of leg muscles, walking aids, and breathing training can help to relieve shortness of breath. There were mixed results for the use of acupunctureրacupressure. Further interventions identifi ed were counseling and support, either alone or in combination with relaxation-breathing training, music, relaxation, a hand-held fan directed at a patient's face, case management, and psychotherapy. There are several nondrug methods available to relieve shortness of breath in incurable stages of cancer and other illnesses. There are currently not enough data to judge the evidence for these interventions.
ARF 5 acute respiratory failure; CHF 5 congestive heart failure; CPAP 5 continuous positive airway pressure; CS 5 case study; CVF 5 chronic ventilatory failure; LTOT 5 long-term oxygen therapy; NPPV 5 noninvasive positive pressure ventilation; PLB 5 pursed-lip breathing; PMR 5 progressive muscle relaxation. See Appendices 1 and 2 for expansion of other abbreviations. The most commonly endorsed barriers were "I'd rather concentrate on staying alive," and "I'm not sure which doctor will be taking care of me." Two barriers were signifi cantly associated with lack of communication, as follows: "I don't know what kind of care I want," and "I'm not sure which doctor will be taking care of me." The greater the number of barriers endorsed by patients, the less likely they were to have discussed end-of-life care with physicians ( P , .01), suggesting the validity of these barriers. Conversely, the more facilitators, the more likely patients were to report having had end-of-life discussions with their physicians ( P , .001). Curtis et al 92 ր2002 RS; Family members of deceased patients; N 5 252
Appendix 3-continued
Effective communication Higher QODD questionnaire scores were signifi cantly associated with death at home ( P , .01), death in the location the patient desired ( P , .01), lower symptom burden ( P , .001), and better ratings of symptom treatment ( P , .01). Although the total score was not associated with the presence of an advance directive, higher scores were associated with communication about treatment preferences ( P , .01), compliance with treatment preferences ( P , .001), and family satisfaction regarding communication with the health-care team ( P , .01). Availability of a health-care team member at night or on weekends was also associated with a higher QODD score ( P , .001). 
